Loading...
NPI 1700120938 · Waterford, MI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ark Laboratory LLC is a clinical medical laboratory provider located in Waterford, Michigan. This profile covers 113 Medicare and 157 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Ark Laboratory LLC |
| Address | 6620 Highland Rd. |
| City | Waterford |
| State | MI |
| ZIP | 48327 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 9, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $38.5M |
| Medicare | $1.6M |
Payer mix is heavily skewed toward Medicaid: the provider reports $38.5M in lifetime Medicaid revenue versus $1.6M in lifetime Medicare revenue, indicating ARK LABORATORY LLC operates as a Medicaid-dominant testing provider rather than a Medicare-focused lab. This imbalance implies most volume and business risk are tied to state Medicaid contracts and reimbursement patterns.
Revenue concentration is high within a few codes on both payers: the top 3 Medicare codes account for 59.3% of the provider's Medicare revenue, led by K1034 ($550.1K, 37.5%), G0480 ($171.5K, 11.7%), and 87798 ($148.6K, 10.1%). On Medicaid the top 3 codes account for 58.3% of Medicaid revenue, led by G0483 ($10.9M, 29.0%), U0003 ($6.1M, 16.2%), and G0480 ($4.9M, 13.1%), showing reliance on a small set of high-yield services.
The code mix signals a laboratory operation focused on high-volume toxicology and infectious-agent molecular testing: dominant codes include G0483, G0480, G0482, and 80307 for definitive and presumptive drug testing, alongside U0003/U0005 and multiple amplified nucleic acid probe codes for SARS–CoV‑2 and multiplex respiratory testing. This combination is consistent with a centralized reference lab or high-throughput diagnostics vendor that processes large numbers of specimens for both drug screening programs and infectious disease surveillance.
ARK LABORATORY LLC is a major statewide player in Medicaid drug and COVID testing: G0483 ranks #2 of 62 providers in-state (98th percentile; extreme outlier), G0480 ranks #2 of 151 providers in-state (99th percentile; extreme outlier), and 80307 ranks #1 of 235 providers in-state (100th percentile; extreme outlier). Those rank/percentile labels indicate the provider’s Medicaid volumes for these codes are far above typical state peers and suggest dominant share in those service lines within Michigan.
By contrast, the provider’s Medicare footprint is comparatively modest despite a few high-percentile code positions; K1034 is the single largest Medicare revenue driver ($550.1K, 37.5%) and ranks #215 of 30143 providers nationally (99th percentile; typical, unremarkable volume). Several other Medicare codes (G0480, 80307, G0482 and common lab panels) appear at high national percentiles but are described as typical volumes, which—combined with the small absolute Medicare total ($1.6M)—portrays ARK as a modest national participant on Medicare rather than a dominant national lab.
Several Medicaid codes are explicitly flagged as statistical outliers in-state and appear across different testing modalities: U0003 is #3 of 157 in-state (98th percentile; extreme outlier), 87798 is #1 of 84 in-state (100th percentile; extreme outlier), and U0005, G0482 and other molecular panels are notably above typical state volumes. These labels suggest a recurring pattern of unusually large Medicaid billing for both molecular infectious testing and definitive drug testing relative to in-state peers.
Claim volumes reported for key Medicaid codes are extremely large—examples include 83.3K claims for G0483, 90.9K claims for U0003, and 150.5K claims for 80307—supporting the inference of a high-throughput operation with substantial specimen handling and reporting capacity. High claim counts combined with high per‑claim payments on some definitive drug-testing codes (e.g., $131 avg paid/claim for G0483) indicate the business model is volume-driven across both low-cost presumptive screens and higher-reimbursement definitive assays.
The provider has an established enrollment history with NPI enumeration on 2012-11-09 (~14 years ago), which is consistent with having had time to scale state-focused testing relationships and build the throughput reflected in the Medicaid billing profile. Tenure combined with the concentrated code mix strengthens the interpretation of an established lab operation specialized in toxicology and molecular diagnostics for state payers.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
113 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 45,840 | $10 | $550.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,530 | $110 | $171.5K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4,370 | $30 | $148.6K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 660 | $190 | $128.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,830 | $60 | $111.8K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 420 | $150 | $64.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 1,320 | $30 | $44.8K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 3,310 | $10 | $26.5K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 1,640 | $20 | $26.2K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 790 | $30 | $22.8K |
Showing 1–10 of 113
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 113 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
113 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0482 | 8 | 50 | 140 | $190 | $109.1K |
| 87798 | 3 | 20 | 380 | $30 | $107.7K |
| K1034 | 7 | 1,090 | 560 | $10 | $64.6K |
| G0480 | 2 | 30 | 270 | $110 | $63.5K |
| G0481 | 11 | 40 | 120 | $150 | $62.1K |
| 87481 | 2 | 10 | 130 | $30 | $27.2K |
| 84134 | 10 | 10 | 70 | $10 | $26.3K |
| 87637 | 10 | 20 | 80 | $140 | $23K |
| 80307 | 6 | 120 | 130 | $60 | $21.3K |
| 87563 | 3 | 10 | 130 | $30 | $17.7K |
Showing 1–10 of 113
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
157 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 83,330 | $130 | $10.9M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 90,920 | $70 | $6.1M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 82,310 | $60 | $4.9M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 46,680 | $100 | $4.8M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 150,530 | $30 | $4.5M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16,570 | $90 | $1.5M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 17,600 | $70 | $1.2M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 49,860 | $20 | $947.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 6,120 | $60 | $355K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 1,800 | $200 | $352.8K |
Showing 1–10 of 157
How this provider's Medicaid billing volume and revenue compare to other Michigan providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Michigan median
157 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 5 | 10 | 160 | $180 | $2.3M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 60 | 1,310 | $130 | $1.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 70 | 680 | $100 | $604K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3 | 160 | 2,720 | $60 | $546.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 50 | 650 | $80 | $298.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 45 | 130 | 1,180 | $80 | $231.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 150 | 2,250 | $30 | $202.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 38 | 180 | 2,600 | $20 | $162K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 60 | 140 | 290 | $80 | $161.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 37 | 190 | 2,610 | $20 | $160.2K |
Showing 1–10 of 157
Other providers in the same ZIP code as Ark Laboratory LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Community Programs Inc. | MI | Substance Abuse Rehabilitation Facility | $0 | $26.5M |
| Progressive Lifestyles, Inc. | MI | Home Health Agency | $0 | $15.8M |
| New Gateways, Inc. | MI | Developmentally Disabled Services Day Training Agency | $0 | $9M |
| Waterford Surgical Center, LLC | MI | Ambulatory Surgical Clinic/Center | $483.7K | $296.5K |
| Jeffrey Dudovitz | MI | Optometrist | $67K | $485.8K |
| James Gibson | MI | Internal Medicine Physician | $174.8K | $0 |
| Lawrence Macdonald | MI | Pulmonary Disease Physician | $173.8K | $0 |
| William Harder | MI | Cardiovascular Disease Physician | $132.1K | $0 |
| John Dickey | MI | Cardiovascular Disease Physician | $128.9K | $0 |
| Miguelangelo Perez Cruet | MI | Specialist | $105.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.